Results
1
-
1
of
1
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents
,
Psychopharmacology
[DOI: 10.1007/s00213-010-2124-0]